Shots:

• The companies collaborated to enable innovative, evidence-based solutions & provide validated clinical machine learning models to identify lung cancer leading to earlier diagnosis & treatment
• The agreement is based on the 2021 agreement b/w Roche & EarlySign which originally focused on a personalized health solution for early detection of gastric cancer
• EarlySign's LungFlag, highly accurate models is intended to assist providers in concentrating additional effort on enriched sub-populations & determining care pathways so that follow-up screenings can be more precisely prescribed in a cost-effective manner

Ref: PRNewswire | Image: Roche